Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Cancer Immunotherapy Market: By Product Type, By Cancer Type and Geography
Cancer Immunotherapy Market: By Product Type, By Cancer Type and Geography
Cancer Immunotherapy Market size was valued at US$ 120 billion in 2023. It is expected to reach a value of US$ 304 billion by 2029, growing at a CAGR of 14.2% from 2024-2030. The global market provides a detailed overview of the cancer immunotherapy market and that can be segmented by product type and cancer type. By product type, the cancer immunotherapy market has been segmented into oncolytic viral therapies & cancer vaccines, monoclonal antibodies, and immunomodulators. The oncolytic viral therapies & cancer vaccines segment is likely to be the largest and fastest-growing segment in terms of product type. Based on cancer type, the cancer immunotherapy market is segmented into breast and lung. Among these, the breast segment is expected to have the fastest-growing market during the forecast period.
Study Period
2024-2030Base Year
2023CAGR
14.2%Largest Market
North AmericaFastest Growing Market
Asia-Pacific
Some of the key factors boosting the market growth include rising spending on healthcare needs, a surge in cancer cases, increasing R&D efforts in the field of cancer immunotherapy, and increasing use of modern cancer therapy alternatives. Moreover, immunotherapy is becoming more popular and has strong growth potential in developing nations.
By region, the Asia Pacific market is expected to witness the highest market share during the forecast period due to an increase in healthcare spending, a rise in per capita income, and improvements to the healthcare system. North America held a considerable market share during the estimated period owing to an increase in the number of cancer patients, an increase in the use of immunotherapy, and the development of bioinformatics tools.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 120 billion |
|
Market Size in 2029 |
US$ 304 billion |
|
Market CAGR |
14.2% |
|
By Product Type |
|
|
By Cancer Type |
|
|
By Region |
|
Download Free Sample Report
The global cancer immunotherapy market size was valued at US$ 120 billion in 2023 and is projected to grow at a CAGR of 14.2% from 2024-2030.
The major players in the global cancer immunotherapy market are Amgen, Inc., Astrazeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily and Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA and Novartis AG.
Asia Pacific is the fastest-growing region for cancer immunotherapy market
| 1.Executive Summary |
| 2.Global Cancer Immunotherapy Market Introduction |
| 2.1.Global Cancer Immunotherapy Market - Taxonomy |
| 2.2.Global Cancer Immunotherapy Market - Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Cancer Type |
| 2.2.3. By Region |
| 3.Global Cancer Immunotherapy Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Cancer Immunotherapy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Cancer Immunotherapy Market By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Oncolytic Viral Therapies & Cancer Vaccines |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Monoclonal Antibodies |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immunomodulators |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Cancer Immunotherapy Market By Cancer Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Breast |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lung |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Cancer Immunotherapy Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 8.1.2.Monoclonal Antibodies |
| 8.1.3.Immunomodulators |
| 8.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Breast |
| 8.2.2.Lung |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 9.1.2.Monoclonal Antibodies |
| 9.1.3.Immunomodulators |
| 9.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Breast |
| 9.2.2.Lung |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 10.Asia Pacific (APAC) Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 10.1.2.Monoclonal Antibodies |
| 10.1.3.Immunomodulators |
| 10.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Breast |
| 10.2.2.Lung |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 11.1.2.Monoclonal Antibodies |
| 11.1.3.Immunomodulators |
| 11.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Breast |
| 11.2.2.Lung |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Cancer Immunotherapy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Oncolytic Viral Therapies & Cancer Vaccines |
| 12.1.2.Monoclonal Antibodies |
| 12.1.3.Immunomodulators |
| 12.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Breast |
| 12.2.2.Lung |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Amgen, Inc |
| 13.2.2.Astrazeneca, PLC |
| 13.2.3.Bayer AG |
| 13.2.4.Bristol-Myers Squibb Company |
| 13.2.5.Eli Lily and Company |
| 13.2.6.Hoffmann-La Roche, Ltd. (Genentech, Inc.) |
| 13.2.7.Pfizer, Inc. |
| 13.2.8.Johnson & Johnson (Janssen Global Services, LLC) |
| 13.2.9.Merck KGAA |
| 13.2.10.Novartis AG |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.